Clene Inc. (NASDAQ:CLNN – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $33.25.
A number of research analysts have issued reports on CLNN shares. HC Wainwright restated a “buy” rating on shares of Clene in a research note on Monday. Weiss Ratings upgraded shares of Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Roth Capital restated a “buy” rating on shares of Clene in a research report on Thursday, May 14th. Finally, D. Boral Capital reissued a “buy” rating and set a $23.00 target price on shares of Clene in a research note on Monday, May 4th.
View Our Latest Stock Report on Clene
Clene Stock Performance
Clene (NASDAQ:CLNN – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.71). The company had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.06 million. As a group, equities analysts forecast that Clene will post -1.58 earnings per share for the current year.
Institutional Investors Weigh In On Clene
Several institutional investors have recently bought and sold shares of CLNN. Jane Street Group LLC acquired a new stake in shares of Clene in the second quarter worth approximately $47,000. State Street Corp raised its position in Clene by 138.4% in the fourth quarter. State Street Corp now owns 29,801 shares of the company’s stock valued at $175,000 after purchasing an additional 17,300 shares during the period. PEAK6 LLC purchased a new stake in Clene in the 4th quarter valued at about $294,000. Geode Capital Management LLC raised its stake in shares of Clene by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock valued at $482,000 after acquiring an additional 6,090 shares during the period. Finally, Scoggin Management LP lifted its stake in Clene by 42.7% during the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock worth $558,000 after purchasing an additional 42,750 shares in the last quarter. 23.28% of the stock is currently owned by institutional investors and hedge funds.
Clene Company Profile
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).
Further Reading
- Five stocks we like better than Clene
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.
